Clinical Trial

Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-09-27; most recent amendment 2026-05-05.
Status change: Recruiting → Active, Not Recruiting 2026-05-05
Status change: Not Yet Recruiting → Recruiting 2025-03-05
Trial Details
NCT Number NCT06621251
Lead Sponsor Trellis Bioscience LLC
Conditions Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Enrollment 60 participants
Start Date 2025-04-08
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-07